TKNO Stock Analysis: Buy, Sell, or Hold?
TKNO - Alpha Teknova, Inc. Common Stock
$2.71
-0.12 (-4.24%)
▼
5d:
-2.87%
30d:
+18.86%
90d:
-32.08%
BUY
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When TKNO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TKNO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: TKNO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TKNO is currently trading at $2.71, which is considered slightly high relative to its 30-day fair value range of $2.22 to $2.86.
Technical Outlook: Technically, TKNO is in a strong downtrend. Immediate support is located at $2.55, while resistance sits at $3.22. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: TKNO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.00 (+232.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TKNO is in a strong downtrend. Immediate support is located at $2.55, while resistance sits at $3.22. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: TKNO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.00 (+232.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$2.22 -
$2.86
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.7%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.2%)
- BULLISH: Trading 232.1% below Wall St target ($9.00)
Fair Price Analysis
30-Day Fair Range
$2.22 -
$2.86
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.55
Resistance Level
$3.22
Current Trend
Strong Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.69
Wall Street Target
$9.00
(+232.1%)
Revenue Growth (YoY)
7.8%
Profit Margin
-42.6%
Share & Embed Analysis
Last updated: March 30, 2026 8:56 AM ET
Data refreshes hourly during market hours. Next update: 9:56 AM
Data refreshes hourly during market hours. Next update: 9:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TKNO showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Stephen Gunstream
BUY
26000 shares
2026-03-06
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 60 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 58 HOLD |
